DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Raises Price Target to $275

Cantor Fitzgerald analyst Alethia Young reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $262 to $275.

Benzinga · 03/11/2020 10:27

Cantor Fitzgerald analyst Alethia Young reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $262 to $275.